Use of carbapenems against clinical, nontyphoid Salmonella isolates: Results from In Vitro and In Vivo animal studies

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2916-2922

  Tang, Hung Jen ^a,d   Chen, Chi Chung ^a,c   Zhang, Chun Cheng ^a   Cheng, Kuo Chen ^a   Chiang, Shyh Ren ^a   Chiu, Yu Hsin ^a   Ku, Yee Huang ^a   Ko, Wen Chien ^b   Chuang, Yin Ching ^a  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARBAPENEM; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; EX VIVO STUDY; EXUDATE; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR KILLING; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SALMONELLA; SURVIVAL RATE;

ANIMALS; BETA-LACTAMS; CARBAPENEMS; CELL LINE; FEMALE; IMIPENEM; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PERITONITIS; SALMONELLA; THIENAMYCINS;

EID: 84861108525     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00110-12     Document Type: Article

References (37)

1. Barry B, et al. 1996. Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:1977-1982. (Pubitemid 26296232)
2. Buckley MM, Barradell RN, Goa KL. 1992. Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44:408-444.
3. Capoor MR, et al. 2009. Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp. J. Med. Microbiol. 58:337-341.
4. Chang HR, Vladoianu IR, Pechere JC. 1990. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim-sulphamethoxazole on Salmonella typhi within human monocyte-derived macrophages. J. Antimicrob. Chemother. 26:689-694.
5. Chen PL, et al. 2007. Extraintestinal focal infections in adults with Salmonella enterica serotype Choleraesuis bacteremia. J. Microbiol. Immunol. Infect. 40:240-247.
6. Chiu LM, Menhinick AM, Johnson PW, Amsden GW. 2002. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J. Antimicrob. Chemother. 50:1075-1079. (Pubitemid 36032835)
7. Cirillo I, et al. 2009. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J. Clin. Pharmacol. 49:798-806.
8. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Crump JA, et al. 2011. Antimicrobial resistance among invasive nontyphoidal Salmonella enterica isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007. Antimicrob. Agents Chemother. 55:1148-1154.
10. Cuffini AM, et al. 1993. The entry of meropenem into human macrophages and its immunomodulating activity. J. Antimicrob. Chemother. 32:695-703. (Pubitemid 23343753)
11. Helms M, Vastrup P, Gerner-Smidt P, Molbak K. 2002. Excess mortality associated with antimicrobial drug-resistant Salmonella Typhimurium. Emerg. Infect. Dis. 8:490-495. (Pubitemid 34533326)
12. Hilliard JJ, et al. 2011. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model. Antimicrob. Agents Chemother. 55:836-844.
13. Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. 2005. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J. Antimicrob. Chemother. 56:1163-1165. (Pubitemid 43009842)
14. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. 2005. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob. Agents Chemother. 49:1337-1339. (Pubitemid 40463358)
15. Kim A, Banevicius MA, Nicolau DP. 2008. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother. 52:2497-2502. (Pubitemid 351915681)
16. Ko WC, et al. 2005. A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis. Clin. Infect. Dis. 40:315-318.
17. Koc E, Turkyilmaz C, Atalay Y, Sen E. 1997. Imipenem for treatment of relapsing Salmonella meningitis in a newborn infant. Acta Paediatr. Jpn. 39:624-625. (Pubitemid 27440859)
18. Lee HY, et al. 2009. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob. Agents Chemother. 53:2696-2699.
19. Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH. 1992. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:993-996.
20. Liu CY, Huang YT, Liao CH, Hsueh PR. 2008. In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan. Antimicrob. Agents Chemother. 52:2677-2679. (Pubitemid 351915708)
21. Lund ME, Blazevic DJ, Matsen JM. 1973. Rapid gentamicin bioassay using a multiple-antibiotic-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 4:569-573.
22. Majumdar AK, et al. 2002. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. 46:3506-3511. (Pubitemid 35192918)
23. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. 2005. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 52:165-171. (Pubitemid 41133541)
24. Menashe O, Kaganskaya E, Baasov T, Yaron S. 2008. Aminoglycosides affect intracellular Salmonella enterica serovars Typhimurium and Virchow. Antimicrob. Agents Chemother. 52:920-926. (Pubitemid 351358371)
25. Moczygemba LR, Frei CR, Burgess DS. 2004. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin. Ther. 26:1800-1807. (Pubitemid 40089493)
26. Moon YS, Chung KC, Gill MA. 1997. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin. Infect. Dis. 24(Suppl. 2):S249-S255. (Pubitemid 27130714)
27. Norrby SR. 1995. Carbapenems. Med. Clin. North Am. 79:745-759.
28. Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC. 1990. Effect of renal function on the bioavailability of ciprofloxacin. Antimicrob. Agents Chemother. 34:1031-1034. (Pubitemid 20177349)
29. Santos Filho L, Kuti JL, Nicolau DP. 2007. Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. Braz. J. Microbiol. 37:183-193. (Pubitemid 47037402)
30. Su LH, et al. 2011. Increasing ceftriaxone resistance in Salmonellae, Taiwan. Emerg. Infect. Dis. 17:1086-1090.
31. Su LH, et al. 2005. Increasing ceftriaxone resistance in Salmonella isolates from a university hospital in Taiwan. J. Antimicrob. Chemother. 55:846-852.
32. Tang HJ, et al. 2011. Tigecycline against clinical nontyphoid Salmonella isolates: comparisons of in vitro and in vivo intracellular killing with ceftriaxone. Antimicrob. Agents Chemother. 55:2755-2759.
33. van den Bogaard AE, Bruinsma N, Stobberingh EE. 2000. The effect of banning avoparcin on VRE carriage in The Netherlands. J. Antimicrob. Chemother. 46:146-148. (Pubitemid 30466214)
34. Xuan D, et al. 2002. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. 46:2990-2995.
35. Yan JJ, et al. 2003. Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosporinase, Taiwan. Emerg. Infect. Dis. 9:323-328.
36. Zhanel GG, Branham RC. 1988. Third-generation cephalosporins. Can. J. Hosp. Pharm. 41:183-194.
37. Zhanel GG, Simor AE, Vercaigne L, Mandell L. 1998. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can. J. Infect. Dis. 9:215-228. (Pubitemid 28435078)